Comparing Monoclonal Antibody Imaging and CT for Melanoma Detection
Author Information
Author(s): A.T. Elliott, R.M. MacKiel, T. Murray, V.R. Doherty, F.G. Adams
Primary Institution: University Department of Dermatology and Departments of Clinical Physics and Bio-engineering and of Radiology, Western Infirmary, Glasgow, UK
Hypothesis
Is the sensitivity and specificity of radiolabelled monoclonal antibodies superior to that of computerised tomography in detecting metastatic melanoma?
Conclusion
Both radiolabelled monoclonal antibodies and CT scans detect approximately 80% of melanoma metastases, with some cases where monoclonal antibodies provided additional clinically relevant information.
Supporting Evidence
- Of 62 known metastases, the antibody detected 50 (81%), with 17 false positive results.
- In eight patients, both methods were considered of equal value.
- In 10 patients, the monoclonal antibody provided more clinically relevant information.
- In three patients, clinically significant lesions were detected by the monoclonal antibody that were not seen by CT.
Takeaway
Doctors used a special dye to see if they could find cancer spots in people with melanoma better than a regular scan. They found that both methods worked pretty well.
Methodology
The study involved injecting a radiolabelled monoclonal antibody into 25 patients and comparing the imaging results with those from CT scans.
Potential Biases
The observers interpreting the scans had no knowledge of the other test results, which may introduce bias in the interpretation.
Limitations
Some patients had false positives and false negatives, particularly in the lungs, and the study did not account for all possible variations in imaging techniques.
Participant Demographics
Patients were adults with stage 2 or stage 3 malignant melanoma.
Want to read the original?
Access the complete publication on the publisher's website